PT  - JOURNAL ARTICLE
AU  - Bradley J. Ahrens
AU  - Lin Li
AU  - Alexandra K. Ciminera
AU  - Junie Chea
AU  - Erasmus Poku
AU  - James R. Bading
AU  - Michael R. Weist
AU  - Marcia M. Miller
AU  - David M. Colcher
AU  - John E. Shively
TI  - Diagnostic PET Imaging of Mammary Microcalcifications Using <sup>64</sup>Cu-DOTA-Alendronate in a Rat Model of Breast Cancer
AID  - 10.2967/jnumed.117.190850
DP  - 2017 Sep 01
TA  - Journal of Nuclear Medicine
PG  - 1373--1379
VI  - 58
IP  - 9
4099  - http://jnm.snmjournals.org/content/58/9/1373.short
4100  - http://jnm.snmjournals.org/content/58/9/1373.full
SO  - J Nucl Med2017 Sep 01; 58
AB  - The development of improved breast cancer screening methods is hindered by a lack of cancer-specific imaging agents and effective small-animal models to test them. The purpose of this study was to evaluate 64Cu-DOTA-alendronate as a mammary microcalcification-targeting PET imaging agent, using an ideal rat model. Our long-term goal is to develop 64Cu-DOTA-alendronate for the detection and noninvasive differentiation of malignant versus benign breast tumors with PET. Methods: DOTA-alendronate was synthesized, radiolabeled with 64Cu, and administered to normal or tumor-bearing aged, female, retired breeder Sprague–Dawley rats for PET imaging. Mammary tissues were subsequently labeled and imaged with light, confocal, and electron microscopy to verify microcalcification targeting specificity of DOTA-alendronate and elucidate the histologic and ultrastructural characteristics of the microcalcifications in different mammary tumor types. Tumor uptake, biodistribution, and dosimetry studies were performed to evaluate the efficacy and safety of 64Cu-DOTA-alendronate. Results: 64Cu-DOTA-alendronate was radiolabeled with a 98% yield. PET imaging using aged, female, retired breeder rats showed specific binding of 64Cu-DOTA-alendronate in mammary glands and mammary tumors. The highest uptake of 64Cu-DOTA-alendronate was in malignant tumors and the lowest uptake in benign tumors and normal mammary tissue. Confocal analysis with carboxyfluorescein-alendronate confirmed the microcalcification binding specificity of alendronate derivatives. Biodistribution studies revealed tissue alendronate concentrations peaking within the first hour, then decreasing over the next 48 h. Our dosimetric analysis demonstrated a 64Cu effective dose within the acceptable range for clinical PET imaging agents and the potential for translation into human patients. Conclusion: 64Cu-DOTA-alendronate is a promising PET imaging agent for the sensitive and specific detection of mammary tumors as well as the differentiation of malignant versus benign tumors based on absolute labeling uptake.